Announced Wed, 3 Jun · 10:34 IST

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gattu Gnana Prakash & Others

Promoter Stake BuyPromoter Below 50pctOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+13.5%1-day move
₹52.00
prior close
₹55.97
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-1.3-1.3-1.7+13.5+26.0+30.4+48.1+47.3+61.0+48.2+49.9
Up moveDown movePending
AI summary

Novelix Pharmaceuticals has reported a disclosure under SEBI's Takeover Regulations regarding shares allotted to its promoter group on 29th May 2026 through conversion of warrants issued on a preferential basis. Gattu Gnana Prakash received 50,000 shares, raising his holding from 3,50,000 to 4,00,000 shares (1.67% of voting capital). Arati Gattu received 1,00,000 shares, taking her holding from 0 to 1,00,000 shares (0.42%). Neha Gattu did not receive any shares in this allotment but still holds 1,00,000 warrants. The total promoter group holding remains at 6,00,000 shares (2.09% of the company). The company's total equity share capital increased from 2.10 crore to 2.39 crore shares as warrants across all allottees were converted.

Likely market impact

This is a routine regulatory disclosure triggered by the conversion of previously issued warrants. It signals that the promoter group is increasing its direct equity exposure, although their overall stake in the company remains small at around 2%. The dilution from the larger warrant conversion is a mild overhang, but the promoter participation shows continued confidence from the founding family.